ReviewNature reviews. Rheumatology2014
The skeletal muscle arachidonic acid cascade in health and inflammatory disease.
Review in Nature reviews. Rheumatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 114 citations in OpenAlex.
- Arachidonic acid metabolism in spinal cord injury.Journal of advanced research · 2026Review
- Hippocampal Mitochondrial Dysfunction and Synaptic Disruption Link Organophosphate Exposure to Pre-Diabetes: An LC-MS/MS-Based Proteomics Approach.Biomolecules · 2026Article
- Dietary omega-6 arachidonic acid and omega-3 docosahexaenoic acid supplementation differentially impact skeletal muscle inflammaging in mice.bioRxiv : the preprint server for biology · 2026Article
- Reactivity of mammalian lipoxygenases (ALOX isoforms) with phospholipids, biomembranes and lipoproteins.Communications biology · 2026Article
- Long-chain Polyunsaturated Fatty Acids MitigatebioRxiv : the preprint server for biology · 2026Article
- Establishment of Three Different Glycation-Damage Cell Models and Analysis of Their Action Mechanism.Metabolites · 2026Article
- A multi-tiered workflow for examining organic acid profiles delineates tissue-specific changes in fatty acyl partitioning during aging.Cell reports methods · 2026Article
- Spike protein-induced VSIR-ISX signaling disrupts metabolic homeostasis and promotes COVID-19-related immune dysfunction.Cell biology and toxicology · 2025Article
- Dietary supplementation of arachidonic acid promotes humoral immunity.EMBO molecular medicine · 2025Article
- Mitochondrial glutamic-oxaloacetic transaminase (GOT2) in the growth of C2C12 myoblasts.Journal of bioenergetics and biomembranes · 2025Article
- Functional Foods, a Hope to Delay Muscle Dystrophy Progression: A Potential Role for Omega Fatty Acids.Nutrients · 2025Review
- Protective impact of circulating ω-3 PUFAs on sepsis susceptibility throughFrontiers in medicine · 2025Article
- Fecal Microbiota Transplantation Activity ofFoods (Basel, Switzerland) · 2024Article
- ω-6 and ω-3 Polyunsaturated Fatty Acids: Inflammation, Obesity and Foods of Animal Resources.Food science of animal resources · 2024Review
- LC/MS-Based Untargeted Lipidomics Reveals Lipid Signatures of Sarcopenia.International journal of molecular sciences · 2024Article
- Article
- Developing a ceRNA-based lncRNA-miRNA-mRNA regulatory network to uncover roles in skeletal muscle development.Frontiers in bioinformatics · 2024Article
- Altered metabolic profiles of dermatomyositis with different myositis-specific autoantibodies associated with clinical phenotype.Frontiers in immunology · 2024Article
- The Interplay of Lipid Signaling in Musculoskeletal Cross Talk: Implications for Health and Disease.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Metabolic profiling of patients with different idiopathic inflammatory myopathy subtypes reveals potential biomarkers in plasma.Clinical and experimental medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Muscle atrophy and weakness are often observed in patients with chronic inflammatory diseases, and are the major clinical features of the autoimmune myopathies, polymyositis and dermatomyositis. A general understanding of the pathogenesis of muscle atrophy and the impaired muscle function associated with chronic inflammatory diseases has not been clarified. In this context, arachidonic acid metabolites, such as the prostaglandin and leukotriene subfamilies, are of interest because they contribute to immune and nonimmune processes. Accumulating evidence suggests that prostaglandins and leukotrienes are involved in causing muscular pain and inflammation, and also in myogenesis and the repair of muscles. In this Review, we summarize novel findings that implicate prostaglandins and leukotrienes in the muscle atrophy and weakness that occur in inflammatory diseases of the muscles, with a focus on inflammatory myopathies. We discuss the role of the arachidonic acid cascade in skeletal muscle growth and function, and individual metabolites as potential therapeutic targets for the treatment of inflammatory muscle diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.